Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Abexinostat (Primary) ; Pazopanib (Primary)
- Indications Renal cell carcinoma; Sarcoma; Solid tumours
- Focus Adverse reactions
- 28 Jul 2017 Planned End Date changed from 1 Oct 2015 to 1 Jan 2020.
- 28 Jul 2017 Planned primary completion date changed from 1 Oct 2015 to 1 Jan 2019.
- 28 Jul 2017 Status changed from completed to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History